iGlobe, a Singapore-based cross-border venture capital firm with deep expertise in tech and bio, has just announced that it has closed its latest venture capital fund at $100 million. The firm plans to use the fund to focus on startups geared towards synthetic biology, FinTech, and developing new and innovative tech for smart cities.

This is the firm’s fourth fund, iGlobe Platinum Fund III. According to a statement by the firm, it plans to invest in roughly 15 to 20 companies across the United States, Europe, and Southeast Asia. The firm already has plans to invest in the following companies: cloud-based cancer diagnostic platform C2i Genomics, San Francisco-based FinTech platform NerdWallet, Singapore-based continual learning network for doctors Docquity, and Filipino digital bank Tonik.

iGlobe was established by Koh Soo Boon in Silicon Valley back in 1999. A decade later, she decided to move the firm’s headquarters back to her home country, Singapore. Since then, the firm has made numerous investments with companies such as Matterport, Ginkgo Bioworks, and Hippo Enterprises. These companies are all planning to go for a US IPO with Matterport, a California-based company that provides a 3D media platform used to establish 3D and virtual reality models, planning to go public in a $2.9 billion deal.

In an interview, Koh comments on the firm’s investments: “We focus on cross-border deep tech, which other people can’t easily copy. We are in the business of building companies rather than just making a quick buck.”

According to Koh, iGlobe may back companies in women’s healthcare, mental healthcare, and 3D printing startups in the future.

Managing Partner Yoke Sin Chong said: “iGlobe is often the sole investor from Asia in the investment deals it is involved in. Our global network allows us to facilitate as the bridge between the Western and Asian startup ecosystems.”

Featured image credits: Unsplash